| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Microbiology and
Animal Resources Center, Montana State University, Bozeman, MT 59717; and
Research Institute for Children, Children’s Hospital, Louisiana State University Health Sciences Center, New Orleans, LA 70118
A/B toxins, produced by bacteria and plants, are among the deadliest molecules known. The B chain binds the cell, whereas the A chain exerts the toxic effect. Both anti-A chain and anti-B chain Abs can neutralize toxins in vivo and in vitro. B chain Abs block binding of the toxin to the cell. It is not known how anti-A chain Abs function. Working with ricin toxin, we demonstrate that immunization with A chain induces greater protection than immunization with B chain. A panel of mAbs, binding to A chain, B chain, or both chains, has been produced and characterized. Immunologic characteristics evaluated include isotype, relative avidity, and epitope specificity. The ability to inhibit ricin enzymatic or cell binding activity was studied, as was the ability to block ricin-mediated cellular cytotoxicity on human and murine cell lines. Finally, the in vivo protective efficacy of the Abs in mice was studied. The Ab providing the greatest in vivo protective efficacy was directed against the A chain. It had the greatest relative avidity and the greatest ability to block enzymatic function and neutralize cytotoxicity. Interestingly, we also obtained an anti-A chain Ab that bound with high avidity, blocked enzymatic activity, did not neutralize cytotoxicity, and actually enhanced the in vivo toxicity of ricin. Anti-A chain Abs with moderate avidity had no in vivo effect, nor did any anti-B chain Abs.
This article has been cited by other articles:
|
|
 |
|
  K. Surendranath and A. A. Karande A Neutralizing Antibody to the A Chain of Abrin Inhibits Abrin Toxicity both In Vitro and In Vivo Clin. Vaccine Immunol., May 1, 2008; 15(5): 737 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perosa, E. Favoino, C. Vicenti, F. Merchionne, and F. Dammacco Identification of an Antigenic and Immunogenic Motif Expressed by Two 7-Mer Rituximab-Specific Cyclic Peptide Mimotopes: Implication for Peptide-Based Active Immunotherapy J. Immunol., December 1, 2007; 179(11): 7967 - 7974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Mantis, C. R. McGuinness, O. Sonuyi, G. Edwards, and S. A. Farrant Immunoglobulin A Antibodies against Ricin A and B Subunits Protect Epithelial Cells from Ricin Intoxication. Infect. Immun., June 1, 2006; 74(6): 3455 - 3462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. McGuinness and N. J. Mantis Characterization of a Novel High-Affinity Monoclonal Immunoglobulin G Antibody against the Ricin B Subunit. Infect. Immun., June 1, 2006; 74(6): 3463 - 3470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Vitetta, J. E. Smallshaw, E. Coleman, H. Jafri, C. Foster, R. Munford, and J. Schindler A pilot clinical trial of a recombinant ricin vaccine in normal humans PNAS, February 14, 2006; 103(7): 2268 - 2273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Smith, J. Lou, I. N. Geren, C. M. Forsyth, R. Tsai, S. L. LaPorte, W. H. Tepp, M. Bradshaw, E. A. Johnson, L. A. Smith, et al. Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization Infect. Immun., September 1, 2005; 73(9): 5450 - 5457. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
